Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Rohtesh S. Mehta(The University of Texas MD Anderson Cancer Center), Baldeep Wirk(Boston University), Olle Ringdén(Karolinska Institutet), Leo F. Verdonck(Isala), Melhem Solh(Johns Hopkins Hospital), James Gajewski(The University of Texas MD Anderson Cancer Center), Attaphol Pawarode(University of Michigan), Vaibhav Agrawal(City Of Hope National Medical Center), Andrew Daly, Gerhard Hildebrandt(University of Missouri Health System), Navneet S. Majhail(Sarah Cannon), Rodrigo Martino(Universitat Autònoma de Barcelona), Yoshihiro Inamoto, Saurabh Chhabra(Medical College of Wisconsin), Medhat Askar(Baylor University Medical Center), Ibrahim Ahmed(Children's Mercy Hospital), Amin M. Alousi(McGill University), Shernan G. Holtan(University of Minnesota), Thomas R. Spitzer(Harvard University), Peiman Hematti(UW Health University Hospital), Zachariah DeFilipp(Harvard University), Takanori Teshima(Hokkaido University Hospital), Michael Hemmer(McGill University), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Sachiko Seo(National Cancer Center Hospital East), Joseph H. Antin(Dana-Farber Cancer Institute), Mukta Arora(Fairview Health Services), Kirk R. Schultz(University of British Columbia), Lynette Chee(The Royal Melbourne Hospital), Taiga Nishihori(Moffitt Cancer Center), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Stephen R. Spellman(National Marrow Donor Program), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Usama Gergis(Thomas Jefferson University Hospital), Hisham Abdel‐Azim(University of Southern California), Richard F. Olsson(AstraZeneca (Netherlands)), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), William J. Hogan(Mayo Clinic), Jan Storek(University of Washington), Jeffery J. Auletta(Nationwide Children's Hospital), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert Peter Gale(Imperial College London), Bipin N. Savani(Vanderbilt University Medical Center), Tao Wang(Medical College of Wisconsin), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), A. Samer Al‐Homsi(NYU Langone Health), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Hélène Schoemans(KU Leuven), Joseph Pidala(Moffitt Cancer Center), Tim Prestidge(Starship Children's Health)
Cited by 50
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
|New England Journal of Medicine|2008|972